

10 Publikationsliste

1. Theresa L Whiteside, Andrea Gambotto, **Andreas Albers**, Joanna Stanson and Edward P. Cohen. Human Tumor-Derived Genomic DNA Transduced into a Recipient Cell Induces Tumor-Specific Responses Ex Vivo. (*accepted with revisions for publication in PNAS 2002*)
2. Odoux C, **Albers A**, Amoscato A, Lotze MT and Wong MK. TRAIL, FasL and a blocking anti-DR5 antibody augment Paclitaxel-induced apoptosis in Human Non-Small-Cell Lung Cancer. *International Journal of Cancer*, 2002 Feb 1;97(4):458-65
3. Wittig B, Marten A, Dorbic T, Weineck S, Min H, Niemitz S, Trojaneck B, Flieger D, Kruopis S, **Albers A**, Loffel J, Neubauer A, Albers P, Muller S, Sauerbruch T, Bieber T, Huhn D, Schmidt-Wolf IG. Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial. *Human Gene Therapy*, 2001 Feb 10;12(13):267-78
4. Thomas Tüting and **Andreas Albers**. Particle-mediated Gene Transfer into Dendritic Cells: A Novel Strategy for the Induction of Immune Responses against Tumor Antigens. In *Gene Therapy of Cancer*. Editors: Walther, W., Stein, U. 2/2000 Humana Press
5. A. Kaiser, M. Wolf-Breitinger, **A. Albers**, T. Dorbic, B. Wittig, E.O.Riecken and S. Rosewicz. Retinoic acid receptor gamma1 expression determines retinoic sensitivity in pancreatic carcinoma cells. *Gastroenterology*, 1998 Oct: 115(4):967-77
6. Odoux C, **Albers A**, and Wong MK. Angiogenesis: molecular mechanisms in cancer; an update in therapies. *Review*, (*submitted*)
7. Odoux C, **Albers A**, Wong, M, Feldman A, Libutti, S and Lotze MT. Activated-human blood-derived dendritic cells produce decreasing amount of angiogenic factors with maturation (*in preparation, 2002*).
8. Odoux C, **Albers A**, Lotze MT, Watkins S and Wong, M. Immature DC induce angiogenesis in vivo (*in preparation, 2002*)

Posterpublikationen

1. Kazuaki Chikamazu, **Andreas Albers**, Ettore Appella, Theresa L. Whiteside and Albert B. DeLeo. Analysis of the ex vivo responses of peripheral blood mononuclear cells obtained from HLA-2.1+ normal donors to a panel of CTL-defined wild type sequence p53 peptides. *American Association of Cancer Research 2002, (San Francisco, USA)*
2. Odoux FC., **Albers EA**, Wong MKK. Augmenting apoptosis in Paclitaxel treated human non-small-cell lung cancer with TRAIL, FAS-L and a blocking anti-DR5 antibody. *American Association of Cancer Research 2002, (San Francisco, USA)*

3. Odoux C, **Albers A**, Lotze MT and Wong MKK. Proangiogenic factor secretion by human blood-derived dendritic cells: Regulation by PGE2 and Dexamethasone. *13th Annual Scientific Retreat. University of Pittsburgh Cancer Institute. May 9th 2001 (Pittsburgh, PA, USA).*
4. Odoux C, **Albers A**, Okada H., Gambotto A and Wong MKK. Dendritic cells produce angiogenic factors and are associated with angiogenic blood vessels in vivo. *ASCO, 2001; 20(1):#1067 (San Francisco).*
5. Odoux C, **Albers A**, Lotze MT and Wong MKK. Regulation of proangiogenic factor secretion by human dendritic cells. *Poster-discussion session and awarded at AACR, 2001; 42: #3047 (New Orleans).*
6. Odoux C, **Albers A** and Lotze MT. A new potent immunomodulatory function for dendritic cells (DC's: the production of proangiogenic factors. *Antiangiogenic agent meeting, January 2000 (Dallas, TX, USA)*
7. Cicinnati VR, Dworacki G, Beckebaum S, Bueso P, **Albers A**, Tüting T and DeLeo AB. Impact of p53 wild-type sequence epitope based immunization in a murine carcinogenesis model: Evidence of immunoselection. *Proceedings 91st Annual Meeting American Association for Cancer Research, Vol. 41, 2000, Abstract 5072*
8. Odoux C, **Albers A** and Lotze MT. Human blood derived dendritic cells produce decreasing amounts of angiogenic factors with maturation. *SBT meeting, October 1999 (Boston, MD, USA)*
9. Cicinnati VR, Dworacki G, Tüting T, **Albers A** and DeLeo A.B. Impact of DNA and peptide-pulsed dendritic cell-based vaccines targeting wild-type sequence p53 epitopes on chemically induced carcinogenesis in mice. *Clinical Cancer Research, Nov. Sup., Abstract. 150, 1999*
10. **Albers A**, Dorbic T, Cicinnati VR, Lotze MT and Wittig B. A novel approach for gene therapy and expression studies: The Ballistomagnetic Vector System. *5th National Symposium: Basic Aspects of Vaccines, Abstract A1, 1999*
11. **Albers A**, Koczan D, Wittig B and Thiesen HJ. From Expression of FAS- ligand transduced into porcine islets by ballisto magnetic vector system to transgenic pigs. *28. Jahrestagung der Deut. Gesellschaft für Immunologie, Würzburg, 1998*
12. **Albers A**, Meye A, Dorbic T and Wittig B. Ballisto-magnetic gene transfer of GFP- reporter plasmid into human primary sarkoma cell lines. *European Journal of Cell Biology EJBC Supplement 43 (Vol. 72) 1997*

Zusätzliche wissenschaftliche Arbeiten

1. **A Albers**, T Dorbic, B Wittig. Ballistomagnetischer Gentransfer, Skriptum zum Trainingskurs, *Bezug über Centrum Somatische Gentherapie, 1997, Arnimallee 22, 14195 Berlin-Dahlem*
2. Odoux C, **Albers A**, and Lotze MT. Activated human dendritic cells (DCs) decrease production of proangiogenic factors with progressive maturation. *In vivo veritas, October 1999, Vol. 5 Num. 2 Page 6, Abstract*
3. **Albers A**, Odoux C, Moore K and Lotze MT. The novel cytokine IL-19 decreases endothelin (ET-1) production with maturation of human DCs. *In vivo veritas, December 1999, Vol. 5 Num 4 Page 4, Abstract*
4. **Albers A**, Dorbic T and Wittig B. A novel approach for gene therapy and expression studies: the ballistomagnetic vector system. *In vivo veritas, November 1999, Vol. 5 Num. 3 Page 5, Abstract*